Hexaminolevulinate-assisted blue light cystoscopy (HAL-BLC) has been shown to lower cancer recurrence rates. The research investigated the effect of HAL-BLC on other important outcomes in patients with bladder cancer, including disease progression and early diagnosis of illness during surveillance cystoscopy. A randomized clinical experiment found that using HAL-BLC at the time of surveillance cystoscopy early boosted the detection of malignant lesions, especially those of high grade, as compared to white light cystoscopy. Furthermore, evidence is emerging that the use of HAL-BLC during endoscopic treatment of high-risk tumors might have resulted in decreased rates of progression to muscle invasion, it may be attributed to better risk assessment that led to modifications in treatment strategy. The therapeutic situations for using HAL-BLC are broader than previously known. It is also becoming obvious that the favorable impact of HAL-BLC is likely to extend beyond only lowering cancer recurrence rates, and patients would benefit from the technology at a variety of periods throughout their disease’s care and follow-up.